The Impact of Median Model for End‐Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma

Sarah Bernards, Ryutaro Hirose, Francis Y. Yao, Chengshi Jin, Jennifer L. Dodge, Chiung‐Yu Huang, Neil Mehta – 10 November 2021 – As a result of ongoing regional disparities, the United Network for Organ Sharing (UNOS) implemented policy in May 2019 limiting exception points for waitlisted patients with hepatocellular carcinoma (HCC) to median Model for End‐Stage Liver Disease at transplant in the area surrounding a transplant center minus 3 points (MMAT‐3). The impact of this policy change remains unknown.

Noninvasive Risk Stratification for Nonalcoholic Fatty Liver Disease Among Living Liver Donor Candidates: A Proposed Algorithm

Nilay Danis, Sharon R. Weeks, Ahyoung Kim, Azarakhsh Baghdadi, Maryam Ghadimi, Ihab R. Kamel, Behnam Saberi, Tinsay Woreta, Jacqueline Garonzik‐Wang, Benjamin Philosophe, Ahmet Gurakar, Rohit Loomba – 8 November 2021 – To reduce waitlist mortality, living donor liver transplantation (LDLT) has increased over the past decade in the United States, but not at a rate sufficient to completely mitigate organ shortage. As a result, there are ongoing efforts to expand the living liver donor pool.

Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders

Coskun Ozer Demirtas, Gabrielle Ricco, Osman Cavit Ozdogan, Feyyaz Baltacioglu, Tunc Ones, Perran Fulden Yumuk, Ender Dulundu, Sinan Uzun, Pierro Colombatto, Filippo Oliveri, Maurizia Rosanna Brunetto, Feyza Gunduz – 8 November 2021 – Optimal scoring system for clinical prognostic factors in patients with unresectable hepatocellular carcinoma (HCC) is currently uncertain. We aimed to develop and externally validate an easy to use tool, particularly for this population, and named it the “unresectable hepatocellular carcinoma prognostic index” (UHPI).

Subscribe to